Generic Product News (May 2018)

MAY 22, 2018

CAPECITABINE
MARKETED BY:
Aurobindo Pharma Ltd
COMPARE TO: Xeloda (Genentech)
INDICATION: The FDA has approved the abbreviated new drug application for capecitabine, which is indicated for the treatment of adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.
DOSAGE FORM: Tablets: 150 and 500 mg
FOR MORE INFORMATION: aurobindo.com


TIAGABINE HYDROCHLORIDE
MARKETED BY:
Amneal Pharmaceuticals
COMPARE TO: Gabitril (Cephalon, Inc)
INDICATION: Amneal Pharmaceuticals has launched tiagabine hydrochloride tablets, an AB-rated therapeutic equivalent for Gabitril. Tiagabine hydrochloride is indicated as adjunctive therapy in adults and children 12 years and older for the treatment of partial seizures.
DOSAGE FORM: Tablets: 2, 4, 12, and 16 mg
FOR MORE INFORMATION: amneal.com


CLOBETASOL PROPIONATE SPRAY, 0.05%
MARKETED BY:
Glenmark Pharmaceuticals
COMPARE TO: Clobex Spray, 0.05% (Galderma Laboratories, LP)
INDICATION: The FDA has approved Glenmark’s clobetasol proprionate spray, 0.05%, the generic version of Clobex Spray, 0.05%. Clobetasol proprionate spray is indicated for the topical treatment of moderate-to-severe plaque psoriasis affecting up to 20% body surface area in patients 18 years and older.
DOSAGE FORM: Topical
FOR MORE INFORMATION: glenmarkpharma.com


OSELTAMIVIR PHOSPHATE
MARKETED BY:
Amneal Pharmaceuticals
COMPARE TO: Tamiflu (Roche Group)
INDICATION: Amneal Pharmaceuticals has launched oseltamivir phosphate for oral suspension, the company’s AB-rated therapeutic equivalent for Tamiflu, in a 6-mg/mL strength. Oseltamivir phosphate is indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks and older who have been symptomatic for no more than 48 hours and the prophylaxis of influenza A and B in patients 1 year and older.
DOSAGE FORM: Oral suspension
FOR MORE INFORMATION: amneal.com

SHARE THIS
0